siRNA Delivery to the Glomerular Mesangium Using Polycationic Cyclodextrin Nanoparticles Containing siRNA by Zuckerman, Jonathan E. et al.
NUCLEIC ACID THERAPEUTICS 
Volume 00, Number 0, 2015 
© Mary Ann Liebert, Inc. 
DOI: 10.1089/nat.2014.0505 
Original Article 
siRNA Delivery to the Glomerular Mesangium Using 
Polycationic Cyclodextrin Nanoparticles Containing siRNA 
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There is an urgent need for new therapies that can halt or reverse the course of chronic kidney disease with minimal 
side-effect burden on the patient. Small interfering RNA (siRNA) nanoparticles are new therapeutic entities in 
clinical development that could be useful for chronic kidney disease treatment because they combine the tissue-
specific targeting properties of nanoparticles with the gene-specific silencing effects of siRNA. Recent reports have 
emerged demonstrating that the kidney, specifically the glomernlus, is a readily accessible site for nanoparticle 
targeting. Here, we explore the hypothesis that intravenously administered polycationic cyclodextrin nanoparticles 
containing siRNA (siRNA/CDP-NPs) can be used for delivery of siRNA to the glomerular mesangium. We 
demonstrate that siRNA/CDP-NPs localize to the glomernlar mesangium with limited deposition in other areas of 
the kidney after intravenous injection. Additionally, we report that both mouse and human mesangial cells rapidly 
internalize siRNA/CDP-NPs in vitro and that nanoparticle uptake can be enhanced by attaching the targeting ligands 
mannose or transferrin to the nanoparticle surface. Lastly, we show knockdown of mesangial enhanced green 
fluorescent protein expression in a reporter mouse strain following iv treatment with siRNA/CDP-NPs. Altogether, 
these data demonstrate the feasibility of mesangial targeting using intravenously administered siRNA/CDP-NPs. 
Introduction 
CHRONIC KIDNEY DISEASE (CKD) is a widespreadmedica1 condition that for many patients \Vill inevitably pro-
gresses toward end stage renal disease despite tnedical in-
tervention [l]. Even \Vith its often unrelenting course, CKD is 
relatively asymptomatic for the afflicted patient who must 
endure lifelong treat1nent \vith tangible side effects. There is 
an urgent need for new therapies that can stop or reverse the 
course of chronic kidney disease \Vith minimal side-effect 
burden on the patient. Small interfering RNA (siRNA) na-
noparticles are novel therapeutic entities in clinical devel-
opment that could be useful for this indication. siRNA 
nanoparticles combine the tissue specificity characteristic of 
nanoparticle therapeutics [2] with gene-specific silencing 
effects of siRNA [3]. This rational combination of thera-
peutic modalities is a promising strategy for diseases, such as 
CKD, that \Vould benefit from highly specific tissue targeting 
\Vith minimal off-target effects. 
Several reports have highlighted the kidney glomerulus as 
an accessible target for nanoparticle based therapeutics [4]. 
Choi et al., have demonstrated that intravenously (i.v.) ad-
ministered PEGylated gold nanoparticles (under IOOnm) 
have a restricted kidney deposition within the tnesangium [5]. 
Liao et al. sho\ved that i.v. TRX-20-prednisolone loaded li-
posome treatments reduced glomerular mesangial im-
munoglobin A (lgA) and C3 depositions in a mouse model of 
IgA nephritis (ddY mice) [6]. Morimoto et al. reported that a 
single i.v. injection of TRX-20-prednisolone loaded lipo-
somes given to a rat model of human mesangial proliferative 
glomerulonephritis (anti-Thy-1 nephritis model) reduced the 
total glomerular cell number and level of a-smooth muscle 
actin-positive cells at a n1arkedly reduced dose con1pared 
\Vith daily injections of a prednisolone saline solution [7]. 
Kan1ps et al. demonstrated that i.v. doses of dexamethasone-
containing monoclonal anti-E-selectin antibody-targeted im-
munoliposomes (Dexa-AbEsel liposomes) decreased plasma 
blood urea nitrogen levels, g1omen1lar proinflamrnatory gene 
levels, and the percentage of crescent glomeruli in an anti-
glomerular basement 1nembrane glomendonephritis mouse 
model. Notably, Dexa-AbEseI liposome treatment did not 
result in elevation of plasma glucose levels, as \vas observed 
with administration of free dexamethasone [SJ. Suana et al. 
sho\ved that single i.v. administration of lo\v dose myco-
phenolate mofetil-OX7-immunoliposomes (MMF-OX7-
1Ls) resulted in less severe nepluitis, with decreased 1ne-
sangial expansion, compared with free MMF in rat anti-
thymocyte antigen I (Thyl.l) nephritis [9]. Importantly, 
liposomal delivery of MMF required only half the s\andard 
total MMF dose to achieve these therapeutic effects. 
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Altogether, these literature examples demonstrate feasibility 
of nanoparticle therapeutic delivery to the glomerulus with 
reduced off-target effects and toxicities. 
Only t\vo reports of systemically adn1inistered siRNA de-
livery to the glome1ulus have been reported. Shimizu et al. 
have repo1ted "proof of principle" results showing that a 
siRNAfcationic polymer (PLLg) delivery system can reach the 
glomerulus follo\ving intraperitoneal administration [10]. 
Administration of these nanocarriers to lpr mice (mouse lupus 
nephritis model) resulted in the decrease of MAPKl expres-
sion and reduced sclerosis \Vithin the nephritic glomeruli of 
these mice. Hauser et al have demonstrated that coupling of 
siRNA to an antibody can be used for specific siRNA delivery 
to podocytes following i.v. administration [11]. 
\Ve have previously reported that cyclodextrin-containing 
siRNA nanoparticles (siRNNCDP-NPs) quickly accun1ulate 
in the glomemlar basement membrane after i.v. administra-
tion [12]. This nanoparticle formulation (Fig. I) of siRNA 
(not chemically modified) \Vith a cationic, cyclodextrin-
containing polyn1er (CDP)-based delivery vehicle (clinical 
version denoted CALAA-01) has been sho\vn to accunuilate 
in human tumors and deliver functional siRNA from a sys-
temic, i.v. infusion [13]. Given its glomerular localization 
and its clinical utility, \Ve decided to explore the potential of 
this siRNNCDP-NP for siRNA delivery to the mesangium. 
Here, we test the hypothesis that the siRNA/CDP-NPs can 
deliver siRNA to the glomen1lar mesangium to facilitate the 
knockdo\vn of target genes in this tissue compartment. 
Materials and Methods 
Small interfering RNA/CDP nanoparticle formulation 
siRNA nanoparticles were formed by using cyclodextrin-
containing polycations (CDP), adamantane-polyethylene gly-
col (AD-PEG), AD-PEG-mannose, and AD-PEG-transferrin 
as previously described (precomplexation) [14]. Nanoparticles 
\Vere formed in 5% glucose in deionized water at a charge ratio 
of 3 +/- and a siRNA concentration of 2n1g/mL unless 
othenvise indicated. T\venty-one base pair unmodified and 
cyanine 3 (Cy3)-labeled oligos were purchased from Qiagen. 
Sense strand sequences are as follo\vs: siRNA targeting en-
hanced green fluorescent protein (EGFP) (5'-GGCUACG 
UCCAGGAGCGCACC-3') from Novina et al. (2002) [15], 
control siRNA (siCON) (5'-UAGCGACUAAACACAUCAA 
UU-3'), si1RACE (5'-CCUGCGAACACACAAGCUCCU-3'). 
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siRNA/CDP nanoparticles formulated \Vith 80 mole percent 
Cy3-siGL3 and Alexa Fluor 350 (AF350)-CDP were similar 
in size and stability to their nonlabeled counterparts (Sup-
plementary Fig. Sl; Supplementary Data are available online 
at \vww.liebertpub.com/nat). 
Synthesis of AF350-labeled CDP 
CDP (30mg) and Alexa Fluor® 350 succinimidyl ester 
(5 mg, Invitrogen) \Vere transferred to a :flask \vrapped in alu-
minum foil and dried under vacuum for 2 hours; 0.5 mL of 
anhydrous dimethyl snlfoxide and N,N-diisopropylethylamine 
(0.7 ~tL) \Vere subsequently added under argon. The reaction 
was allowed to proceed in the dark under argon \Vith constant 
stining overnight. The reaction 1nixture \Vas dialyzed against 
water three times via a 3-kDa membrane centrifuge filter de-
vice (Amicon), The retentate \Vas then filtered through a 
0.2 µm filter (Palls) and lyophilized to yield a yellow colored 
product. 
Synthesis of AD·PEG·mannose 
Three one hundredths millimoles of H-hydroxysuccin-
intlde-PEG-1naleintlde was added to 0.18mmol of 4-anlino-
phenyl alpha-D-mannopyranoside in phosphate-buffered 
saline (PBS), pH 7.5, and incubated for 1 hour at room tem-
perature. Reaction mixture was then dialyzed against water, 
0.lµm, and lyophilized. One hundred nine milliggrams of 
mannose-PEG-maleirnide and 13.3 mg of admantane-SH were 
dried under vacuum for 1 hour; 2 n1L of anhydrous dimethyl 
sulfoxide \Vas then added under inert gas and reaction was 
incubated overnight at room temperature. Water was added 
and insoluble material \Vas removed by centrifugation. The 
supernatant \Vas dialyzed against \Vater and 0.2 pm filtered and 
purified over 2x TSKgel G3000SWxl columns with PBS pH 
7.2 at 0.5 rnIJrninute as the eluent. The appropriate fraction 
was collected and lyophilized. Structure was verified by proton 
nuclear magnetic resonance and matrix assisted laser desorp-
tion ionization time-of~ftight (Supplementary Fig. S2). 
Cell culture 
SV40-MES (mouse mesangial) and CRL-2573 (rat me-
sangial) cells \Vere obtained fron1 ATCC. Human mesangial 
cells were obtained from ScienCell. For siRNA/CDP NP up-
take experiments, cells seeded in six-well plates \Vere washed 
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FIG. 1. Schematic of small interfering RNA/cyclodextrin-containing polymer nanoparticle (siRNA/CDP-NP) assembly. 
\Vhen mixed together in aqueous solution (5% dextrose), the cationic CDPs assemble \Vith the negatively charged siRNA 
molecules via electrostatic interaction. Five-kilodalton polyethylene glycol (PEG) molecules are covalently linked to the 
small molecule adamantane (AD) and will form guest/host interactions with the cyclodextrin component of the nanoparticle 
thereby providing satiric stabilization to the nanoparticles. The distal end of the AD-PEG 1nolecules can be covalently 
linked to targeting ligands (TL) such as mannose or transfenin that facilitate cellular internalization of the nanoparticles. 
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with PBS and siRNA/CDP NPs suspended in 2 mL of opti-
MEM (Invitrogen) were applied. Total siRNA concentration 
was 100 nM. At the indicated time points the nanoparticle 
solution \Vas ren1oved and the cells washed \Vith cell scrub 
buffer (Gene Therapy Systems) to remove surface associated 
nanoparticles or nucleic acids prior to analysis. Cells \Vere 
imaged directly in the six-well plates for the epifluorescence 
experiments. Cells were trypsinized in 1 x trypsin (Invitrogen), 
washed, and resuspended in PBS for fio\v cytometry experi-
ments, \Vhich were perfonned on a FACSCalibur (BD Bios-
ciences) flo\v cytometer and data analysis was performed using 
Flo\ving Soft\vare version 2.5.1. 
Animal studies 
This study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health. The 
protocol was approved by the Caltech Institutional Animal 
Care and Use Committee (Protocol 1502). Si-6 to nine-week-
old, female Balb/c mice and C57BL/6-Tg(CAG-EGF-
P)10sb/J (Stock No. 003291) mice were obtained for the 
Jackson Laboratory. Mice \Vere euthanized by carbon dioxide 
overdose for organ collection at indicated time points. All 
organs \Vere fixed in 4% (\v/v) parafonnaldehyde in PBS 
overnight. For confocal itnaging, siRNA/CDP NP formula-
tions contain 80 mole percent Cy3-siTRACE and AF350-
CDP were administered via i.v. tail vein injections at a dose 
of 5 or !Omglkg siRNA in -lOOµL injection volume. 
Formalin-fixed organs \Vere dehydrated and embedded in 
molten paraffin to generate sections 4 µmin thickness. 
In vivo EGFP knockdown experiment 
Mice received i.v. doses of transferrin-targeted siRNAJ 
CDP NPs containing control siRNA (siCON), transferrin-
targeted siRNA/CDP NPs containing siEGFP, or nlannose-
targeted siRNA/CDP NPs containing siEGFP at a dose of 
10 mg/kg siRN A on day 1 and 3 of the experiment. Mice 
were killed on day 5 for kidney harvesting and tissue pro-
cessing. Slides \Vere imaged in a blinded fashion with fixed 
detector gain; 70-72 consecutively identified glon1eruli 
from each slide were ilnaged. Data sets were scored prior to 
unblinding. 
Transmission electron m;crocopy 
Tissue blocks (,...., 1 mm3) \Vere fixed in 2.5% glutaralde-
hyde (in 0.1 M sodium cacodylate, pH=7.4) for 2 hours, 
stained by 1 % Os04 at 4°C for 2 hours, and 0.9% osmium 
tetroxide (Os04) and 0.3% potassium ferrocyanide at 4°C for 
2 hours. Gradual dehydration \Vith ethanol and propylene 
oxide enabled tissue embedding in Epon 812 resins (Electron 
Microscopy Sciences); 80·nm-thick sections were deposited 
on carbon and formvar-coated, 200-n1esh, nickel grids and 
stained \Vith 3% uranyl acetate and Reynolds lead citrate for 
visualization under a 300 kV TF30UT transmission electron 
microscope. 
Fluorescent microscopy 
Sections \Vere deparrafinized \Vith xylene, rehydrated, and 
mounted with ProLong Gold antifade reagent (Invitrogen) for 
viewing. 
Confocal microscopy 
Images \Vere obtained on a Zeiss LSM 510 inverted con-
focal scanning microscope (with a Zeiss PlanApochorn1atx 
63/1.4 oil objective). The anti-CD90fihyl (MRC OX-7) 
mouse monoclonal antibody (Abeam: ab225) was used at 
1:100 dilution. The excitation wavelength for AF350-CDP 
and 4' ,6-diamidino-2-phenylindole was 705 nm (two-photon 
laser) and 543 nm (helium-neon laser) for Cy3-siRNA. Their 
corresponding emission filters \Vere 390--465 nm, and 565-
615 nm respectively. The measured resolution at which 
images \Vere acquired is 512x512 pixels, and the image bit-
depth is 8 bits. The Zeiss LSM Image Browser Soft\vare 
allo\vs the extraction of in1ages. 
Epifluorescent microscopy 
Images \Vere obtained on an Olympus IXSO fluorescent 
microscope (\vith an Olympus UPlanfiuor 40X/1.3 oil ob· 
jective). 
Magnetic bead based g/omeru/ar Isolation 
Glomeruli were isolated using the method developed by 
Takemoto et al. [16]. Briefly, mice were perfused with Dy-
nabeads (M-450 tosylactivated) (Invitrogen) suspended in 
PBS immediately post mortem via infusion through the left 
ventricle. Kidneys \Vere subsequently minced \Vith a razor 
blade follo\ved by digestion \Vith collagenase and DNaseI for 
1 hour at 37°C. Digested material \Vas passed through two 
5 µm cell strainers (BD bioscience) and pooled \Vith subse-
quent PBS \vashes of the strainers. Material was pelleted at 
200 g for 10 minutes. The supernatant was decanted and the 
pellet resuspended in PBS. The tube containing the re-
suspended pellet \Vas placed on the magnet (Invitrogen) and 
the magnet bound material was washed three times with PBS. 
Magnet bound material \Vas resuspended in PBS and con-
finned to contain glomeruH via light microscopy, 
RNA isolation and real Ume reverse transcription 
polymerase cha;n reaction 
Total RNA was isolated from cells using the miRNeasy kit 
(Qiagen) following n1anufacturer's instructions and quanti-
fied using a Nanodrop 2000 spectrophotometer (Thermo). 
Custom Taqman n1icroRNA quantitative polymerase chain 
reaction (PCR) assays (Applied Biosystems) for siTrace \Vere 
used for quantification of siRNA frorn total RNA. Reverse 
transcription and PCR reactions were performed as described 
in the product manual. Real-time PCR analysis was per-
formed using a MyiQ Single Color Real Time PCR Detection 
System (Bio-Rad). 
Results 
Rapid siRNA nanoparlicle internalization observed for 
mouse and human mesnagia/ cells in vitro 
To den1onstrate the feasibility that human and 1nouse 
mesangial cells will internalize siRNA/CDP·NPs, we ex-
amined the uptake of siRNA/CDP-NPs by mesangial cells 
in vitro using Cy3-siRNA containing siRNA/CDP-NP for-
n1ul3.tions. Cy3-siRNA fluorescence intensity \Vas measured 
via both epiftuorescence nlicroscopy and flow cytometry. 
Both mouse and human mesangial cells internalized the 
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siRNAfCDP-NPs, but not free siRNA, after only 5 minutes of 
exposure (Fig. 2A; Supplementary Fig. S3A, B). We con-
firmed these observations via flow cytomerty (Fig 2B). \Ve 
also observed siRNA/CDP-NP uptake in rat mesangial cells 
(Supplementary Fig. S3C). 
Intravenously administered siRNNCDP nanopartic/es 
deposit within the mouse kidney mesangium 
To detern1ine whether i.v. adntlnistered siRNAJCDP-NPs 
deposit in the mesangium, we interrogated the level of fluo-
rescent signal present in fixed sections of kidney tissue from 
mice that received i.v. siRNA/CDP-NPs that contain fluo-
rescent components (Cy3-labed siRNA and AF350-labeled 
CDP). Fluorescent signal in the kidney after i.v. administra-
tion of free Cy3-siRNA Vt1as found \Vi thin tubule cells at 10 
rninutes after injection and was nearly undetectable 120 
minutes after injection (Fig. 3A). No detectable fluorescence 
signal \Vas observed in the glomeruli of these 1nice. Ho\vever, 
following i.v. administration of Cy3-siRNA/CDP-NPs the 
opposite phenomenon was observed. Strong Cy3-siRNA 
fluorescence signal \Vas detected within all glomeruli exam-
ined at 10 minutes post injection, with minimal signal in 
tubule cells (Fig. 3A). Although greatly attenuated, Cy3-
siRNA fluorescent signal \Vas still clearly detectable in glo-
1neruli 120 minutes after i.v. administration \Vith minimal 
accumulation in other kidney compartments. \Ve also ob-
served some fluorescent signal in the peritubule interstitial 
space follo\ving siRNA/CDP-NP administration, but not free 
siRNA administration (Supplementary Fig. S4). 
To determine whether these siRNA/CDP-NP formulations 
were depositing as intact nanoparticles in the glomentlus, we 
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examined the glome1ular fluorescent signal from mice re-
ceiving siRNA/CDP-NP forn1ulations containing both Cy3-
siRNA and AF350-CDP (Fig. 3B). Strong AF350-CDP 
fluorescence that colocalized \Vith the Cy3-siRNA signal \Vas 
observed in glomen1li at 10 minutes after injection. Although 
greatly attenuated, colocalized glomerular Cy3-siRNA and 
AF350-CDP fluorescence \Vas still detected in alJ glome1uli 
at 120 minutes post dose. \Ve confirmed these observations 
by transmission electron microscopy analyses that revealed 
electron dense objects in the glo1nerular capillary wall con-
sistent in size and shape \Vith intact siRNA/CDP-NPs (Fig. 
3C). 
To confinn delivery of siRNA/CDP-NPs to the me-
sangium, \Ve counter-stained tissue sections from mice that 
received Cy3-siRNA containing nanoparticles with the n1e-
sangial marker thymie antigen I (Thy!) using the OX-7 
monoclonal antibody (Fig. 3D). We found persistent Cy3-
siRNA fluorescent signal 48 hours after administration of the 
siRNA/CDP-NPs that colocalized with the OX-7 antibody 
staining. Semiquantitative colocalization analysis of Cy3-
siRNA fluorescence and OX-7 staining using BiolmageXD 
soft\vare revealed 88o/o OX7 staining colocalization \Vith 
Cy3-ftuorescnece and 91 % colocalization of Cy3-siRNA 
fluorescence with OX-7 staining. These data suggest that 
siRNA/CDP-NP deposition in the glomerulus is primarily 
mesangial. 
Outside the kidney, siRNNCDP-NPs have restricted 
distribution to liver sinusoids, and splenlc red pulp 
The restricted biodistribution of nanoparticle therapeutics 
is paramount in limiting their off-target toxicities. Therefore, 
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FIG. 2. In vitro uptake of siRNA/CDP-NPs by mouse and hun1an mesangial cells and modulation of uptake with targeting 
ligands. Analysis of in vitro uptake of cyanine 3 (Cy3)-siRNA labeled siRNA/CDP-NPs by mouse or human mesangial cells. 
(A) Epifluorescence microscopy images of mesangial cells follo\ving a 5-ininute exposure to siRNA/CDP-NPs. (B) Flo\v 
cytometcy analysis of Cy3-siRNA fluorescence intensity in mesangial cells follo\ving exposure to siRNA/CDP-NPs for the 
indicated amount of time. Detector gain and exposure tin1e for all epifluorescence in1ages \Vas fixed for each experiment. 
Global brightness and contrast were adjusted across \vhole images to itnprove clarity of itnages on scale for pub1ication. Color 
images available online at \V\V\V.liebertpub.com/nat 
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FIG. 3. siRNA/CDP-NPs accumulate in mouse glomeruli following intravenous (i.v.) administration. (A) Laser scanning 
confocal microcopy of kidney sections from mice that received iv doses of free Cy3-siRNA or Cy3-siRNA labeled siRNA/ 
CDP-NPs. Solid arrows point to glomeruli. (B) High magnification in1ages of glomeruli from 1nice that received iv doses 
siRNA/CDP-NPs dual labeled with Cy3-siRNA/AF350-CDP fluorescent labels. (C) Transmission electron microscopy 
images from the glomerulus of a mouse 10 minutes follo\ving an iv dose of siRNA/CDP-NPs. Black arro\vs point to 
spherical electron dense deposits that are consistent in size \Vith siRNA/CDP-NPs. BM, glomerular basement 1nen1brane; E, 
endothelial cell; FP, podocyte foot process; P, podocyte; R, red blood cell; US, urinary space. (D) Fluorescence microscopy 
itnage of a mouse glomerulus 48 hours after administration of Cy3-siRNA labeled siRNA/CDP-NPs. Tissue section were 
costained for thymic antigen 1 (Thyl) mesangial marker \vith the OX-7 monoclonal antibody. For all· images, the detector 
\vas adjusted for 1naximal dynamic range or until diffuse background autofluorescence in proxitnal tubules \Vas apparent. 
Global brightness and contrast \Vere adjusted across whole ilnages to improve clarity of images on scale for publication. 
Color images available online at \V\V\V.liebertpub.com/nat 
we explored the deposition of the Cy3-siRNA/CDP-NPs in 
other organs (Fig. 4). Bright and diffuse Cy3-siRNA fluo-
rescent signal was observed in liver and spleen, \vhereas only 
focal areas of fluorescent signal nearly indistinguishable from 
tissue background autofluorescence were observed in the 
lung, heart, and pancreas. Moreover, the suborgan level 
distribution in the liver and spleen \Vas also restricted. In the 
liver, the Cy3-siRNA fluorescent signal localized to sinu-
soids, whereas in the spleen, Cy3-siRNA fluorescent signal 
was found solely in the red pulp. The addition of the targeting 
ligands n1annose or transferrin to the siRNA/CDP NPs re-
sulted in a mild increase in liver and spleen deposition 
(Supplementary Fig. SS). Our results are consistent with 
previously reported data from real-time positron emission 
tomography studies that showed siRNA/CDP-NPs primarily 
depositing in liver and kidney [17]. 
Surface targeting ligands increase mesangial cell 
uptake of siRNAICDP-NPs in vitro and alter 
lntraglomerufar distribution in vitro 
Surface targeting ligands have been demonstrated to im-
prove the cellular internalization efficiencies of nanoparticles 
[18]. We hypothesized that addition of a targeting ligand to 
the siRNA/CDP-NPs \vould result in increased mesangial 
cell uptake. Therefore, \Ve tested mesangial cell uptake of 
siRNNCDP-NPs formulated \Vith t\VO different surface tar-
geting ligands: (I) the sugar mannose and (2) the iron 
transport protein, transferrin. \Ve chose the mannose target-
ing ligand because, \Vithin the kidney, the expression of the 
mannose receptor (MR) is restriction to mesangial cells 
[19,20]. The transfen·in targeting ligand \Vas chosen because 
\Ve have previously demonstrated its ability to enhance in-
tracellular uptake of the siRNA/CDP-NPs in other cell lines 
in vitro and in vivo [17,21]. Ho\vever, transferrin receptor is a 
niore general receptor expressed by many cell types, but not 
highly in the healthy glomerulus [22]. 
Epifluorescence experiments qualitatively demonstrated 
similar n1esangial cell uptake for the targeted siRNA/CDP-
NPs as compared \Vith nontargeted nanoparticles (Fig. 2A). 
To more carefully quantify the amount of intracellular Cy3-
siRNA fluorescence, we employed fl.ow cytometry (Fig. 2B). 
\Ve observed higher intracellular Cy3-siRNA fluorescence 
intensities in mouse mesangial cells treated \Vith transferrin-
targeted siRNA/CDP-NPs than those treated with untargeted 
siRNA/CDP-NPs (fluorescence peak mean intensity 47 .3 ± 
14.1 versus 29.3±0.3; p<0.05). However, transferrin-
targeted siRNNCDP-NP treatment did not result in increased 
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FIG. 4. siRNAfCDP-NPs 
have a restricted biodistribu- Spleen 
tion outside the kidney. Laser 
scanning confocal microcopy 
of tissue sections fron1 the 
indicated organs taken from 
mice at 10 and 120 minutes 
after administration of i.v. 
doses of Cy3-labeled siRNAf 
CDP-NPs or CDP polymer. 
For all images, detector gain 
was adjusted for maximal dy- lung 
namic range or until diffuse 
background autofluorescence 
was apparent. Global bright-
ness and contrast were ad-
justed across whole images to 
improve clarity of images on 
scale for publication. IL, Islets 
of Langerhans; PV, portal vein; 
RP, red pulp; WP, white pulp. 
Color images available online 
at ww\v.liebertpub.coni/nat Pancreas 
Heart 
intracellular Cy3-siRNA fluorescence compared \Vith un-
targeted siRNA/CDP NP treatment in human mesangial cells. 
Unlike treatment \Vith transferrin-targeted siRNA/CDP NPs, 
treatn1ent with the mannose-targeted siRNA/CDP-NPs re-
sulted in increased intracellular Cy3-siRNA fluorescence in 
both mouse and human rnesangial cells compared \Vith un-
targeted siRNA/CDP-NPs (fluorescence peak mean intensity 
58.2±2.1 vs. 29.3±0.3; p<0.05) and (90.4± 12.3 vs. 43.1 ± 
17.0; p < 0.05), respectively. 
\Ve investigated \vhether the presence of targeting ligands 
altered the in vivo intrakidney distributions of the siRNA/ 
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CDP-NPs. Fluorescence rnicrocopy on fixed tissue sections 
(Fig. 4C, D) and quantitative PCR measurements (Fig. 5) 
\Vere used in these studies. Epifluorescence microscopy im-
aging was used to examine the distribution and intensity of 
the Cy3-siRNA fluorescence signal in glomeruli at 10 and 
120 minutes after i.v. administration of untargeted siRNA/ 
CDP-NPs and mannose-targeted siRNNCDP-NPs (Fig. SA). 
At 120 minutes after i.v. administration there \Vas a marked 
attenuation in glomerular fluorescent signal in kidneys fron1 
mice treated \Vith untargeted siRNAJCDP-NPs. This attenu-
ation in glomerular signal at 120 ntlnutes post treatn1ent \Vas 
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FIG. 5. In vivo uptake of matutose or transferrin targeting siRNA/CDP-NPs. (A) Epiftuorescence microscopy images of kidney 
sections from mice that received Cy3-siRNA labeled siRNA/CDP-NPs or siRNA/CDP-NPs \vith mannose targeting ligands. 
Arrows point to glomeruli. (Il) Laser scanning confocal microscopy in1ages of kidney sections from mice 2 hours after i.v. 
treatment with siRNA/CDP-NPs, Tf-siRNA/CDP-NPs, or Mn-siRNA/CDP-NPs. siRNA/CDP-NPs, untargeted siRNA/CDP-NPs; 
TF-siRNA/CDP-NPs, transferrin-targeted siRNA/CDP-NPs; Mn-siRNA/CDP-NPs, mannose-targeted siRNA/CDP-NPs. De-
tector gain and exposure time for all epifluorescence images \Vas fixed for each experiment. Detector gain for all confocal images 
was adjusted for maxin1al dynamic range or until diffuse background autofluorescence in proxi1nal tubules was apparent. In1ages 
with more visible background are lo\ver in overall fluorescence intensity. Global brightness and contrast were adjusted across 
whole images to improve clarity of images on scale for publication. Color images available online at \V\V\V.liebertpub.com/nat 
not observed in the kidneys of mice treated with mannose-
targeted siRNNCDP-NPs. These data suggest that mannose 
targeting of nanoparticles resulted in a longer glon1erular 
residency time for the rnannose-targeted siRNA/CDP-NPs. 
Figure 5B demonstrates that glomentlar fluorescence inten-
sity at 120 minutes post treatment in the kidneys of mice 
treated \Vith transferrin-targeted siRNA/CDP-NPs \Vas simi-
lar to untargeted siRNA/CDP-NPs and markedly less than the 
fluorescence intensity of the mannose-targeted siRNA/CDP-
NPs. These data suggest that inclusion of a transferrin tar-
geting ligand did not result in longer glomerular residency 
times for the siRNA/CDP-NPs. 
To more quantitatively assess delivery of targeted siRNA/ 
CDP-NPs to the glomerulus, we used quantitative PCR to 
interrogate the level of siRNA present in isolated glomeruli 
from mice receiving i.v. administration of the different siR-
NA/CDP-NP formulations (Fig. 6). siRNA present in whole 
RNA extracts from these glomen1li \Vas detected using a 
custom Taqman real-time PCR probe to detect the presence 
of the antisense strand of a specific siRNA sequence (si-
Trace). Glomerular RNA extracts fro1n mice treated \vith 
transferrin-targeted siRNA/CDP-NP \Vith a control siRNA 
sequence (siCON) that is not recognized by the Taqman PCR 
probe \Vere used as background controls. 
\Ve first examined the glomen1li from mice 1 and 3 days 
after received i.v. doses of free siTrace. At 1 day post dose, 
siTrace \Vas detectable in RN A extracts from these glorneruli 
at levels 12-fold above background. At 3 days post dose, 
siTrace signal in glornerular RNA extracts from this treat-
ment group were not significantly above background. \Ve 
next examined glornen11i from mice that received iv. doses of 
various siRNA/CDP-NP formulations. At 1 day post dose, si-
Trace signal in glomerular RNA extracts fro1n the nontargeted 
siRNA/CDP-NP treatment group was found to be 333-fold 
higher than the siTrace signal detected in the free siTrace 
treatment group. The amount of siTrace signal in the glorner-
uli from mice treated with transferrin- or mannose-targeted 
siRNA/CDP-NPs (356- and 274-fold above background 
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FIG. 6. Quantitative real-
time polymerase chain reaction 
B l Da¥ 11ost dose 3 0a¥S 11ost dose (PCR) detection of siRNA de-
livery to the glomerulus. (A) 
Light micrographs of two .____. p;0,07 
preparations of isolated glo-
• • p;0.390 p<0.05 memli from mouse kidneys. 
(B) Real-time PCR based de- -~ pc0,380 .____. p<0.05 
tection of siTrace in isolated l.E;-00 +---+ 
glomeruli from ntlce 1 and 3 
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siCON group is a background c x 
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CDP-NPs \Vith siTrace; Mn- ~ .. NP siTrace, mannose-targeted 1.E·02 
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respectively) was not significant different from the amount 
detected in the nontargeted siRNA/CDP-NP group. At 3 days 
post dose, siTrace signal in the glomeruli fro1n both the 
transferrin- and mannose-targeted siRNNCDP-NPs \Vas still 
significantly higher than siTrace signal detected in the free 
siRNA treatment group. Although transferrin-targeting lead 
to a 12-fold increase in total siTrace signal in glomeruli 
compared \Vith mannose targeting, these results \Vere not 
significantly different. 
siRNAICDP-NPs silenced gene expression 
in the mesangium 
\Ve next examined th~ ability oftransferrin- and mannose-
targeted siRNNCDP-NPs to silence EGFP expression in the 
p<0.05 1.Ef-00 
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glomeruli of EGFP expressing transgenic ntlce. \Ve used 
fluorescence microscopy to examine EGFP fluorescence in 
kidney sections from each mouse (Fig. 7). A microscopy-
based analysis \Vas chosen to facilitate specific analysis of 
mesangial EGFP expression. \Ve used a blinded, semiquan-
titative, glomerular fluorescence scoring analysis to deter-
mine the level of EGFP expression in the glomerulus. 
Fluorescence micrographs of 70-72 glomeruli from each 
mouse \Vere taken and scored as high, intennediate, or lo\v 
EGFP fluorescence (representative examples of each scoring 
category are pictured in Supple1nentary Fig. S6C). 
Once scores had been assigned to all imaged glomeruli, the 
data \Vere unblinded and results from each treatment group 
\Vere averaged and cotnpared. Kidneys from mice receiving 
the siRNA/CDP-NPs containing control siRNA (siCON) 
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\Vere found to have strong expression of EGFP throughout 
their kidneys. Glomentlar EGFP expression was found to be 
higher than tubules. \Vithin the glomeruli, cells in the glo-
menilar periphery (likely podocytes) had more pronounced 
EGFP expression than more central glomerular cells (likely 
mesangial areas) (Supplementary Figure S6A, B). Transferrin-
and mannose-targeted siRNAJCDP-NPs containing siEGFP 
were found to reduce glomerular EGFP expression. EGFP 
knockdown \Vas most noticeable within the central region of 
the glomerulus (likely mesangial region). A ~2-fold decrease 
of glomeruli \Vith high EGFP expression was observed in both 
transferrin- and mannose-targeted siRNA/CDP-NP treatment 
groups. A ,....,6-fold increase in the number of glomeruli with 
lo\V EGFP expression \Vas observed in the transfe1Tin-targeted 
siRNA/CDP-NP treated mice, \vhereas only a "'3-fold non-
significant increase \Vas noted in the mannose-targeted siRNAJ 
CDP-NP treatment group. Ho\vever, a significant increase in 
the number of glomemli \Vith intern1ediate EGFP expression 
FIG. 7. Evidence for gene silencing in the 
kidney mesangium follo\ving intravenous 
administration of siRNA/CDP-NPs. (A-B) 
Analysis of enhanced green fluorescence 
protein expression (EGFP) in EGFP-
expressing transgenic mice following i.v. 
dosing of siRNA/CDP-NPs with siRNA 
against EGFP (siEGFP) or control siRNA 
(siCON). (A) Fluorescence micrographs of 
median intensity glomeruli from each mouse 
in the experin1ent. White arrows point to glo-
men11i. Tf-NP-siEGFP, transferrin-targeted 
siRNA/CDP-NPs with siEGFP; Mn-NP-
siEGFP, mannose-targeted siRNA/CDP-NPs 
with siEGFP. (B) Results of semiquantita-
tive scoring analysis of glo1nerular EGFP 
fluorescence intensities. For each mouse, 
70-72 glomen11i were imaged and scored as 
high, intennediate, or lo\V EGFP fluores-
cence (representative examples of each scor-
ing category are pictured in Supplementary 
Fig. S2). All in1aging and sco1ing were per-
formed blind. The average nun1ber of glo-
meruH fron1 each scoring bin are sho\vn, 
Error bars are standard deviation; n=3; 
p values are results of one-tailed t-tests. Color 
in1ages available on1ine at W\VW.liebertpub 
.co1n/nat 
was noted only in the tnannose-targeted siRNA/CDP-NP 
treatment group. Altogether, these data demonstrate gene 
knockdo\vn in the mesangium follo,ving i.v. siRNA/CDP-NP 
adtninistration. 
Discussion 
Taken in total, the results from our studies demonstrate the 
feasibility of siRNA delivery to the mesangiu1n following i.v. 
administration of siRNA/CDP-NPs. Using confocal tnicros-
copy, \Ve demonstrated the presence of Cy3-siRNA in the 
glomeruli of mice that received i.v. doses of siRNA/CDP-
NPs, but not in the glomeruli of mice that received free 
siRNA. Additionally, we showed that the siRNA/CDP-NPs 
deposit in the g1on1erulus as intact nanoparticles as evidenced 
by the colocalization of Cy3-siRNA and AF350-CDP fluo-
rescence in the glomerulus as \Vell as electron micrographs of 
nanoparticle sized objects in the glomerular capillary \Vall. 
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Colocalization of Cy3-siRNA fluorescence and OX-7 anti-
body staining for Thyl antigen confirmed mesangial delivery 
of the siRNA. Biodistribution studies demonstrated a re-
stricted deposition outside the kidney Ii1nited to liver sinu-
soids (likely in Kupffer cells [23]) and splenic red pulp. 
Fu1ihermore, ,ve demonstrated that both 111ouse and human 
1nesangial cells can rapidly internalize the siRNA/CDP-NPs 
but not free siRNA in vitro and that uptake of the siRNA/ 
CDP-NPs by mesangial cells can be enhanced by surface 
targeting ligands. Lastly, \Ve sho\ved that i.v. doses of siRNA/ 
CDP-NPs resulted in decreased mesangial expression of 
EGFP in a EGFP-reporter mouse strain. 
To our kno\vledge, our study is only the second reported 
example of polymer-nanoparticle mediated siRNA delivery 
to the mesangium following systentic administration. The 
first, perfonned by Shimizu et al. den1onstrated that non-
targeted 10-nm siRNA/cationic polymer micelles can reach 
the glomen1lus foJJo,ving intraperitoneal administration (10]. 
Our study builds upon this \VOrk by demonstrating the fea-
sibility of using i. v. adntinistration as \vell as larger 
( ~ 70 nm) polymer-based nanoparticles to target the me-
sangium. Moreover, the siRNA/CDP-NPs used here have 
previously been demonstrated to deliver function siRNA to 
patient tumor tissue follo\ving i.v. administration in the 
clinic, and therefore the results presented here have direct 
translational relevance. \Ve suggest that the siRNA/CDP-NPs 
could be useful for mesangial delivery of siRNA in humans. 
Given that the ultrastructure of the glomentlus across mam-
malian species is nearly identical [24], we speculate that our 
observations in the mouse kidney would be applicable to 
delivery to htunan kidney inesangium. Also, we showed that 
human n1esangial cells n1ore readily uptake the siRNA/CDP-
NPs than n1ouse mesangial cells in vitro. 
\Ve investigated if the surface targeting ligands transferrin 
or mannose could be used to increase mesangial uptake of the 
siRNA/CDP-NPs. Mannose receptor expression in the kid-
ney is restricted to the mesangium [19,20] and has been 
demonstrated to facilitate uptake of nanoparticles by mac-
rophages in vivo (25,26]. The transfeni.n receptor, although 
up-regulated \Vithin the mesangium of patients \Vith lgA 
nephropathy [27-29], is not highly expressed in the healthy 
glomerulus, but has been den1onstrated to facilitate intra-
cellular uptake of the transferrin-targeted siRNNCDP-NPs 
in other cell lines [17,21]. 
In vitro, the rnannose targeting ligand enhanced uptake of 
the siRNNCDP-NPs in both n1ouse and human mesangial 
cells, \Vhereas the transferrin receptor only enhanced uptake 
in n1ouse cells. In vivo, mannose targeting resulted in en-
hanced glomerular Cy3-siRNA fluoresce intensity 2 hours 
after i. v. dosing compared \vi th either untargeted or transfenin-
targeted siRNA/CDP-NPs. However, these effects were 
transient as the total amount of siRNA detected in isolated 
glomeruli by PCR 1 day follo\ving i.v. administration \Vas not 
different among the various siRNAfCDP-NP formulations. 
Shnilarly, rnannose targeting did not result in any additional 
benefit in the EGFP knockdo\vn experiment. Surprisingly, 
the PCR quantification data of siRNA delivery to the glo-
n1erulus at 3 days post dose trended higher for the transferrin-
siRNNCDP NP group compared with the mannose-siRNN 
CDP NP group (although statistical significance was not 
achieved). These data suggest that transferrin may be the su-
perior targeting ligand for mesangial targeting. We speculate 
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that mannose targeting may favor trafficking to digestive 
compartments \Vithin the mesangial cell resulting in more ra-
pid degradation of the siRNNCDP-NPs. Nontargeted, trans-
ferrin-targeted, and some fraction of the mannose-targeted 
siRNNCDP-NPs may be taken up through alternate pathways 
(e.g., endocytosis, macropinocytosis, calveolar transport) that 
are more pennissible for endosomal escape and subsequent 
siRNA delivery to the cytoplasm (18]. Further \Vork to eluci-
date this mechanism is merited. 
Several other non-nanoparticle based strategies of siRNA 
delivery to the kidney glomerulus have been reported. Hauser 
et al. have demonstrated that a monovalent lg-protamine 
conjugate could successfully deliver siRNA to normal mu-
rine podocytes in vivo {11]. Yuan et al., have also sho\vn 
that subcutaneous administration of cholesterol conju-
gated phosphorothioate-modified siRNAs targeting 12/15-
lipoxegenase reduced kidney damage in diabetic mice [30]. 
Other reported examples of siRNA delivery to the glomerulus 
and kidney in general have employed less clinically appli-
cable direct renal artery injections [31]. Nanoparticle n1edi-
ated delivery of siRNA can be advantageous over these 
methods due to the highly tunable nature of their pharn1a-
cokinetic, biodistribution, and targeting properties compared 
with free antibodies, phosphorothioate-modified, or other 
free nucleic acids. Theoretically, these properties of nano-
particles should enable more specific control of targeting and 
off-target effects. 
Our study has several limitations. \Ve confined our ex-
periments to healthy mice. It remains to be detennined 
whether the siRNA/CDP NP system can facilitate gene 
knockdown in mouse n1odels of kidney disease. Ho\vever, 
reports examining nanoparticle delivery to the diseased kid-
ney in animal models (6,9,32~35] suggest that nanoparticles 
have a higher propensity for glomerular deposition in glo-
n1en1lonephritic states, likely due to increased vascular per-
meability and inflammation. Thus, the healthy, rather than the 
diseased kidney, may provide the more restrictive condition 
for nanoparticle delivery. Furthermore, many chronic kidney 
diseases such as diabetic nephropathy display fairly subtle 
glomerular morphologic changes in early disease, and \Ve 
speculate that the glon1erular nanoparticle targeting criteria 
may not be significantly altered until advance stage disease. 
Another limitation of the current study is that \Ve only re-
ported mesangial knockdo\vn of a reporter protein (EGFP) in 
a transgenic mouse 1nodel rather than an endogenous, bio-
logically relevant, mesangial protein. \Ve have performed 
follow-up experhnents that demonstrate knockdo,vn of the 
endogenous mesangial protein Orailin mice [36]. Therefore, 
\Ve believe the knockdown of EGFP repo11ed in this study 
\Vill be generalizable to other mesangial protein targets. 
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